X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4.
Lead Product(s): Naptumomab Estafenatox,Docetaxel,Obinutuzumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Translational Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Active Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: NAP
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Active Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2021
Details:
Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: NAP
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Active Biotech
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2020
Details:
The company plans to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox in combination with durvalumab and continue to develop our patented STR platform.
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
